EQ Equillium, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%
Returns
ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $41.09M | $36.08M | $15.76M | — |
| R&D expense | $12.84M | $37.43M | $37.04M | $37.55M | $26.38M |
| SG&A expense | $10.79M | $11.94M | $13.57M | $17.24M | $11.41M |
| Operating income | -$23.63M | -$8.27M | -$14.52M | -$62.08M | -$37.79M |
| Interest expense | — | — | $491,000 | $1.05M | $1.07M |
| Pretax income | -$22.40M | -$7.71M | -$12.76M | -$62.43M | -$39.05M |
| Income tax | $0 | $361,000 | $580,000 | $0 | $0 |
| Net income | -$22.40M | -$8.07M | -$13.34M | -$62.43M | -$39.05M |
| EBITDA | -$23.52M | -$8.13M | -$14.40M | -$61.96M | -$37.71M |
| EPS (basic) | -0.39 | -0.23 | -0.38 | -1.85 | -1.36 |
| EPS (diluted) | -0.39 | -0.23 | -0.38 | -1.85 | -1.36 |
| Weighted avg. shares (diluted) | 57.30M | 35.36M | 34.73M | 33.73M | 28.81M |
| Balance sheet | |||||
| Cash & equivalents | $30.28M | $18.09M | $23.22M | $59.11M | $50.37M |
| Short-term investments | — | $4.49M | $17.65M | $11.92M | $30.34M |
| Receivables | — | $0 | $3.73M | $2.84M | $0 |
| Current assets | $31.04M | $24.98M | $49.35M | $76.73M | $83.37M |
| PP&E, net | $164,000 | $262,000 | $315,000 | $391,000 | $237,000 |
| Total assets | $31.89M | $25.60M | $50.53M | $78.42M | $85.41M |
| Current liabilities | $2.93M | $6.36M | $27.57M | $32.04M | $8.91M |
| Short-term debt | — | — | — | $5.71M | $1.43M |
| Long-term debt | — | — | — | $3.24M | $8.75M |
| Total debt | — | — | — | $8.95M | $10.18M |
| Total liabilities | $3.29M | $6.54M | $27.96M | $46.48M | $18.90M |
| Shareholders' equity | $28.60M | $19.06M | $22.57M | $31.94M | $66.50M |
| Net debt | — | — | — | -$50.15M | -$40.19M |
| Shares outstanding | 61.46M | 35.56M | 35.25M | 34.41M | 29.46M |
| Cash flow statement | |||||
| Operating cash flow | -$22.75M | -$19.03M | -$21.78M | -$8.73M | -$32.08M |
| Capital expenditure | $48,000 | $85,000 | $50,000 | $279,000 | $57,000 |
| Free cash flow | -$22.79M | -$19.11M | -$21.83M | -$9.01M | -$32.14M |
| Investing cash flow | $4.46M | $13.81M | -$4.76M | $18.68M | $27.41M |
| Financing cash flow | $30.43M | $164,000 | -$9.23M | -$1.22M | $31.06M |
| Depreciation & amortization | $116,000 | $137,000 | $126,000 | $118,000 | $72,000 |
| Stock-based compensation | $2.32M | $3.75M | $4.00M | $4.84M | $4.41M |
| Share buybacks | — | — | $260,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.